We focus on some of the most promising medical radioisotopes for targeted radiotherapy. Our innovative equipment and efficient supply chains will allow to improve the accessibility and supply security of GMP-grade radioisotopes worldwide.


nca Lutetium-177 is the most widely used radionuclide for targeted cancer radiotherapy. It is the active substance of 177Lu-PSMA-617 and more than 150 clinical-stage therapeutic drug developments across multiple cancer indications.
nca Lu-177 is a beta emitter with a half-life of 6.7 days that is free of the long-lived 177mLu. Linked to a cancer-specific targeting agent, it can destroy cancer cells over a distance of one millimeter. 


Actinium-225 is currently the most sought-after radioisotope for alphatherapy. It is present in the therapeutic pipeline of many up-and-coming radiopharmaceutical companies.
225Ac is an alpha emitter with a half-life of 9.9 days, which delivers its cell-killing energy over a very short distance of about the thickness of six cells. The similar radiolabeling characterics of Actinium and Lutetium makes 225Ac the natural apha counterpart to 177Lu.


Terbium-161 has garnered great interest in nuclear medicine due to its complementarity with other radiosotopes of the Terbium family: Tb-149 (alpha-emitter), Tb-152 (PET), Tb-155 (SPECT).
161Tb is a beta emitter with a half-life of 6.9 days that shows similar characteristics to nca 177Lu, but may have enhanced short distance cell-killing efficiency due to the co-emission of a larger number of conversion and Auger electrons.

Contact us

To find out more about how to know and exercise your rights, like the withdrawal of your consent to use submitted datas, please check out our privacy policy.

Message Sent!
Thank you for your interest.
We are doing our best to get back to you shortly,
The Global Morpho Pharma team.
Sorry network issue,
please try again
or send us an email:
Thank you